^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN panel has included carfilzomib/rituximab/dexamethasone as a treatment option under other recommended regimens for Primary Therapy.
Secondary therapy:
carfilzomib + dexamethasone
Source:
Excerpt:
Waldenstroms Macroglobulinaemia /Lymphoplasmacytic Lymphoma:...Preferred regimens...Bendamustine/rituximab....Other recommended regimens...Rituximab/cyclophosphamide/dexamethasone....Rituximab/cyclophosphamide/prednisone
Secondary therapy:
bendamustine; prednisone; cyclophosphamide + dexamethasone
